Clarivate (CLVT) Q2 2025: Recurring Revenue Mix Jumps 800bps as Subscription Focus Sharpens
Clarivate’s second quarter marked a decisive shift toward a subscription-driven model, with recurring revenue mix surging and operational focus realigning around core segments. Management’s value creation plan is driving measurable progress in sales execution, product innovation, and cost discipline, while segment-level advances in IP and life sciences suggest early traction from AI investments. With the strategic review nearing its conclusion and organic recurring revenue at 88 percent, Clarivate is positioned for more predictable growth, though ongoing segment transitions and market headwinds warrant close watch into 2026.
Summary
- Subscription Model Realignment: Recurring revenue now dominates, with transactional sales phased out and renewal rates at record highs.
- AI-Driven Product Momentum: New launches and embedded AI capabilities are gaining adoption across academic, IP, and life sciences segments.
- Strategic Review Nears Completion: Business model optimization and disposals set the stage for a more focused, higher-margin Clarivate.
Performance Analysis
Clarivate delivered another quarter of sequential organic growth, as the company’s pivot toward a subscription-first business model took hold across all major segments. Organic annual contract value (ACV, a measure of contracted recurring revenue) grew 1.3 percent year-over-year, with recurring organic revenue up nearly 1 percent, signaling stabilization after prior-year declines. The shift away from transactional sales, especially in Academic & Government (A&G), is materially increasing recurring revenue, now at 88 percent of total revenue for the first half—an 800 basis point improvement year-over-year.
Profitability also improved, with adjusted EBITDA margin expanding 50 basis points to 41 percent for the first half, fueled by internal cost efficiencies and disciplined capital allocation. Free cash flow generation remained robust, supporting $100 million in share repurchases. Segment performance was broadly constructive: A&G posted 2 percent organic ACV and subscription growth, IP returned to positive growth in patent annuities, and Life Sciences & Healthcare (LS&H) saw subscription ACV inflect positively, primarily on the back of AI-enabled product enhancements.
- Recurring Revenue Dominance: 88 percent of revenue is now recurring, reducing volatility and improving predictability.
- Operational Leverage: Cost discipline and business disposals supported margin expansion and cash flow conversion.
- Segment Recovery Signals: IP and LS&H both returned to organic growth, indicating early benefits from product and sales investments.
While inorganic factors (disposals, divestitures, FX) continue to impact reported results, underlying trends point to a leaner, more focused Clarivate.
Executive Commentary
"Our value creation plan is on track with measurable progress across all key initiatives and KPIs. We have launched all major business optimization program to increase cost subscription and reoccurring revenue, which is enhancing sales predictability."
Monty Shintaz, Chief Executive Officer
"Q2 represents the second quarter of sequential organic ACV and recurring revenue growth acceleration. Optimizing our business model by disposing of non-core transactional businesses is creating a laser focus on our core recurring products and services, and we now have tangible evidence of the upward trajectory."
Jonathan Collins, Chief Financial Officer
Strategic Positioning
1. Subscription-First Model Transformation
Clarivate is systematically phasing out transactional sales, particularly in A&G, and converting customers to multi-year, subscription-based solutions such as ProQuest eBooks. Early adoption is strong, with over 70 wins and hundreds of institutions evaluating the new model. This shift not only boosts revenue visibility but also raises renewal rates, which now stand at 96 percent in A&G despite funding pressures in higher education.
2. Accelerated AI Product Innovation
The company launched 10 new AI-powered capabilities since the value creation plan began, embedding agentic AI into research workflow products like Web of Science. Over 4,800 institutions are already using Clarivate’s AI tools, driving operational efficiency and user engagement. Outsell recently recognized Clarivate’s AI leadership among scholarly research organizations, reinforcing its innovation credentials.
3. Segment-Specific Execution and Tailwinds
IP segment returned to growth in patent annuities, benefiting from a surge in AI-related patent filings, especially in Asia. Management expects these trends to support the business over several years, as new filings convert into annuity revenue. In LS&H, investments in the Cortellis suite and commercial analytics platforms are yielding higher retention and usage, particularly among top pharma clients.
4. Operational Efficiency and Portfolio Optimization
Cost actions and business disposals are streamlining operations, with $85 million in operating cost reductions targeted for the year and a narrowed focus on core recurring revenue streams. The ongoing strategic review is expected to conclude by year-end, potentially setting up further portfolio rationalization and capital allocation shifts.
Key Considerations
Clarivate’s quarter reflects a business in transition, with recurring revenue and operational focus improving, but external and internal challenges remain.
Key Considerations:
- Renewal Rate Resilience: Despite U.S. federal agency and university funding constraints, A&G renewal rates remain at all-time highs, underlining the mission-critical nature of Clarivate’s products.
- AI as a Growth Lever: Early adoption and external validation of AI tools suggest Clarivate’s innovation investments are resonating, but continued product differentiation will be key as competitors advance their own AI offerings.
- Segment Diversification and Recovery: IP and LS&H segments are recovering, but the timing of annuity revenue realization and pharma commercial budget cycles introduce lag and uncertainty.
- Execution on Disposals: Some business disposals are taking longer than planned due to customer transition needs, delaying full realization of the new operating model’s benefits.
Risks
Clarivate faces ongoing risks from macroeconomic headwinds in higher education and government funding, regulatory changes in patent fee structures, and the competitive pace of AI product development. Execution on disposals and the ability to sustain high renewal rates will be crucial, while delays or missteps could undermine the predictability and margin gains from the new model. Management’s optimism is grounded in early indicators, but the full impact of market volatility and customer budget cycles remains to be seen.
Forward Outlook
For Q3 2025, Clarivate guided to:
- Continued organic ACV acceleration, targeting 1.5 percent growth at the midpoint for the year
- Adjusted EBITDA margin at approximately 41 percent
For full-year 2025, management reaffirmed guidance:
- Revenue near the top end of the range, driven by recurring mix and slower attrition in disposals
- Free cash flow of $340 million at the midpoint
Management highlighted several factors that will shape the second half:
- Further AI-driven product releases across all segments
- Conclusion of the strategic review, with results to be communicated at year-end
Takeaways
Clarivate’s transformation is yielding early results, with recurring revenue dominance and AI-led innovation setting the stage for a more predictable, higher-margin business.
- Recurring Revenue Pivot: The decisive shift away from transactional sales and focus on high renewal subscription contracts is structurally improving Clarivate’s revenue quality and visibility, as evidenced by the 800 basis point jump in recurring mix.
- AI and Product Investment Payoff: Embedded AI capabilities are driving customer adoption and retention, especially in research and life sciences, but must continue to outpace competitive offerings to sustain momentum.
- Execution Watchpoints: Investors should monitor the pace of business disposals, segment-level recovery in IP and LS&H, and the outcome of the strategic review for signals on future capital allocation and growth potential.
Conclusion
Clarivate’s Q2 results underscore a business at an inflection point, with recurring revenue and operational discipline driving improved performance. The company’s ability to sustain these gains through continued innovation, segment execution, and successful completion of its strategic review will determine the durability of its transformation heading into 2026.
Industry Read-Through
Clarivate’s successful pivot to a subscription-first, AI-enabled model provides a roadmap for other information services and analytics firms navigating similar market and funding pressures. The surge in AI-related patent activity and the embedding of agentic AI tools into workflow solutions signal rising customer expectations for automation and efficiency across research, IP, and healthcare verticals. As academic and corporate clients demand more predictable, value-driven solutions, competitors will need to accelerate their own recurring revenue transitions and invest in differentiated, AI-powered offerings to maintain relevance.